Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Lisdexamfetamine Atc N06Ba12 Obg For The Period 01 08 24 31 07 25 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6367992

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Omalizumab Atc R03Dx05 Obo For The Period 01 08 2024 31 07 2025 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6344888

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Colistin Atc J01Xb01 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6340118

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Medicines Containing The Active Substance Ustekinumab Atc L04Ac05

Deadline: 31 May 2026

Germany

Ref. No.: 6337480

EMD:Ref Document

Bid Value: Ref Document

44 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Albendazole Atc P02Ca03 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6337365

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Pomalidomide Atc L04Ax06 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6335525

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Open House Drug Rebate Agreements Dolutegravir And Rilpivirine Atc J05Ar21

Deadline: 05 Jun 2026

Germany

Ref. No.: 6330837

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Open House Drug Rebate Agreements Pazopanib Atc L01Ex03

Deadline: 05 Jun 2026

Germany

Ref. No.: 6330518

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Open House Drug Discount Agreements Pimecrolimus Atc D11Ah02

Deadline: 05 Jun 2026

Germany

Ref. No.: 6329785

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Lisdexamfetamine Atc N06Ba12 Obg For The Period 01 08 24 31 07 25 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6322269

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Medicines Containing The Active Ingredient Lanthanum Iii Carbonate Atc V03Ae03 In The Dosage Form Chewable Tablets

Deadline: 31 May 2026

Germany

Ref. No.: 6321582

EMD:Ref Document

Bid Value: Ref Document

44 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Omalizumab Atc R03Dx05 Obo For The Period 01 08 2024 31 07 2025 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6320404

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Unlocking A T Cell Mediated Immune Response In Therapy Challenged Tumors

Deadline: 30 Jun 2029

Austria

Ref. No.: 6318639

EMD:Ref Document

Bid Value: Ref Document

1170 Days Left

Demonstrating Innovative Pathways Addressing Water And Soil Pollution In The Mediterranean Agro Hydro System

Deadline: 30 Jun 2028

Greece

Ref. No.: 6318627

EMD:Ref Document

Bid Value: Ref Document

805 Days Left

Open House Drug Rebate Agreements Ribociclib Atc L01Ef02

Deadline: 05 Jun 2026

Germany

Ref. No.: 6317948

EMD:Ref Document

Bid Value: Ref Document

49 Days Left

Discover Tenders by Modelling Pastes Sector

Filter Your Search

Tenders by Countries

Browse Popular Sectors

Projects by Regions

Funding Agency

Support

CONTACT DETAILS

Discover Tenders by Modelling Pastes Sector

Filter Your Search

FREE Trial plan for all new users!